BetterLife Pharma (BETRF) Cash from Financing Activities (2010 - 2026)

BetterLife Pharma's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $186067.1 for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 959.11% year-over-year to $186067.1; the TTM figure through Apr 2026 stood at $337126.2 (down 40.2% YoY), while the FY2026 annual figure was $453427.9, down 67.7% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at $186067.1, up from $127362.4 in the prior quarter.
• The five-year high for Cash from Financing Activities was $1.2 million in Q2 2023, with the low at $120.88 in Q1 2022.
• The 5-year median for Cash from Financing Activities is $191628.8 (2026), against an average of $291743.6.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 99.99% in 2022, then surged 63747.05% in 2023.
• BetterLife Pharma's Cash from Financing Activities stood at $495747.0 in 2022, then sank by 36.42% to $315204.9 in 2023, then plunged by 92.01% to $25190.7 in 2024, then jumped by 405.59% to $127362.4 in 2025, then jumped by 46.09% to $186067.1 in 2026.
• Business Quant data shows BETRF's Cash from Financing Activities at $186067.1 in Q2 2026, $127362.4 in Q3 2025, and $17568.2 in Q2 2025.